EGRX Eagle Pharmaceuticals Inc.

58.06
+1.6  (+3%)
Previous Close 56.46
Open 56.99
Price To Book 4.6
Market Cap 793,499,053
Shares 13,666,880
Volume 215,922
Short Ratio
Av. Daily Volume 137,706

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pilot trial planned, to be followed by pivotal trial.
Fulvestrant
Breast cancer
Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.
PEMFEXY,
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
CRL issued July 26, 2017. Additional trial required.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Ryanodex
Malignant hyperthermia - cancer
Intends to meet with FDA June 2019 to discuss path forward.
Ryanodex
Exertional heat stroke (EHS)
Data released May 7, 2019 noted lower incidence of brain damage.
Ryanodex
Nerve agent (NA) exposure

Latest News

  1. New Strong Buy Stocks for August 14th
  2. Edited Transcript of EGRX earnings conference call or presentation 8-Aug-19 12:30pm GMT
  3. Eagle Pharmaceuticals Inc (EGRX) Q2 2019 Earnings Call Transcript
  4. Eagle Pharmaceuticals (EGRX) Beats Q2 Earnings and Revenue Estimates
  5. Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results
  6. Eagle Pharmaceuticals Announces Clinical Development Plan of Innovative Product Intended to Deliver Maximum Estrogen Receptor Inhibition in Patients with Estrogen Receptor (ER)-Positive Breast Cancer
  7. Earnings Preview: Eagle Pharmaceuticals (EGRX) Q2 Earnings Expected to Decline
  8. Eagle Pharmaceuticals to Discuss Second Quarter 2019 Financial Results on August 8, 2019
  9. Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?
  10. Should You Worry About Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Pay Cheque?
  11. Park Service diverts $2.5 million in fees to pay for Trump’s July 4th celebration | Beto O’Rourke says he’s unaware of his fundraising numbers
  12. See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
  13. Here's Why I Think Eagle Pharmaceuticals (NASDAQ:EGRX) Might Deserve Your Attention Today
  14. Eagle Pharmaceuticals, Inc. to Present at Jefferies 2019 Global Healthcare Conference
  15. Edited Transcript of EGRX earnings conference call or presentation 7-May-19 12:30pm GMT
  16. Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference
  17. Hedge Funds Have Never Been More Bullish On Eagle Pharmaceuticals Inc (EGRX)
  18. Can Eagle Pharma Fly through its Oncology Trials